Tandem’s diabetes care (Nasdaq: TNDM) Price target raised to $ 59.00

Tandem Diabetes Care (Nasdaq: TNDM – Free Report) As if his intended price was removed from Canaccord Genuity Group from $ 58.00 to $ 59.00 in a research note released Thursday morning, Benzinga reports. They currently have a purchase estimate in the shares of the medical equipment company.

Other research analysts have also issued research reports on shares. Royal Bank of Canada reduced their price target in tandem diabetes care shares from $ 65.00 to $ 55.00 and set a “better” rating for the company in a February 27 research note. Robert W. Baird removed their price target in Tandem Diabetes Care shares from $ 33.00 to $ 24.00 and set a “neutral” rating for the company on a research note on Thursday. Wells Fargo & Company lowered their price target in tandem diabetes care from $ 22.00 to $ 20.00 and set up a “equal weight” rating in shares in a search note on Thursday. The Goldman Sachs Group lowered their target price in caring for Tandem diabetes from $ 42.00 to $ 24.00 and put on a “neutral” rating for the company on a research note on Monday, March 3. Finally, Stifel Nicolaus lowered their price target in tandem diabetes from $ 60.00 to $ 31.00 and set a “Buy” rating in shares in a report on Thursday. Eight investment analysts have evaluated shares with a holding rating and nine have assigned a purchase estimate in the company’s shares. According to Marketbeat, Tandem diabetes care has an average estimate of “moderate purchase” and a $ 39.81 consensus price target.

View our latest stock analysis in tandem diabetes care

Performance of Diabetes Care Shares

Nasdaq: TNDM opened with $ 21.48 on Thursday. The company’s 50-day average is $ 18.80 and its average in motion two hundred days is $ 28.57. Tandem diabetes care has a $ 1-year low of $ 15.75 and a 1-year height of $ 53.69. The company has a debt to capital of 1.29, a current ratio of 2.90 and a rapid ratio of 2.32. The firm has a market capitalization of $ 1.43 billion, a price price of -11.13 and a beta of 1.52.

Tandem diabetes care (Nasdaq: TNDM – Get FREE report) released for the last time quarter profits on Wednesday, April 30. The medical equipment company reported (0.67 dollars) EPS for the quarter, losing consensus estimates of analysts of ($ 0.60) with ($ 0.07). The business had revenue of $ 234.42 million during the quarter, compared to the estimates of analysts of $ 220.19 million. Tandem’s diabetes care had a negative difference of 14.84% and a negative return of capital of 44.19%. Company revenues increased 22.3% on the basis of one year a year. During the same quarter in a year ago, the company posted ($ 0.65) revenue per share. Analysts predict that Tandem diabetes care will post -1.68 EPS for the current year.

Purchase and sale in Tandem diabetes care

In other news of diabetes care, Coo Jean-Claude Kyrillos bought 10.538 business stock shares in a March 7 transaction on Friday. The shares were earned at an average cost of $ 18.12 per share, with a total value of $ 190,948.56. After the purchase, the main operating officer now owns 10,538 shares in the company, worth approximately $ 190,948.56. This represents an increase in their position. The transaction was discovered in a document submitted to the SEC, which is accessible through the SEC website. 1.90% of the shares is owned by corporate interior.

Institutional flows and exits

Some major investors have recently purchased and sells business shares. The Arizona State Pension System increased its shares in tandem diabetes care shares by 1.9% during the 4th quarter. The Arizona State Pension System now owns 18,961 shares of the medical equipment company worth $ 683,000 after the purchase of additional 362 shares during this period. The Montreal Bank can increase its properties in the care of Tandem diabetes by 4.3% during the fourth quarter. Montreal Bank can now own 10,004 shares of the medical equipment company worth $ 360,000 after buying an additional 409 shares in the last quarter. Summit Investment Advisors Inc. increased its position in the care of Tandem diabetes by 8.3% during the fourth quarter. Summit Investment Advisors Inc. It now owns 6.870 shares of the medical equipment company worth $ 247,000 after buying 525 additional shares during this period. ASSETMARK INC. increased its possessions in the care of Tandem diabetes by 77.5% in the fourth quarter. ASSETMARK INC. It now owns 1,225 shares of the medical equipment company worth $ 44,000 after purchasing 535 additional shares in the last quarter. Finally, Alphaquest LLC raised its position in Tandem diabetes care shares at 138.7% during the 4th quarter. Alphaquest LLC now owns 931 shares of the medical equipment company worth $ 34,000 after earning an additional 541 shares during this period.

Tandem Profile of Diabetes Care Company

(Get free report)

Tandem Diabetes Care, Inc., a company of medical equipment, designs, develops and commercializes technological solutions for people living with diabetes in the United States and internationally. The company’s flag product is the insulin distribution system T: Slim X2, a pump platform for managing insulin distribution and displaying continuous information of glucose monitoring directly on the initial pump screen; And Tandem Mobi Pump Insulin, an automated insulin distribution system.

Further reading

Get news and evaluations for Tandem diabetes care every day – Set up your email address below to obtain a daily summary of the latest news estimates and tandem diabetes and companies associated with the email newspaper of the Marketbeat.com.